CHMP recommends extension of indication of Humira(AbbVie) in JIA
The CHMP recommends that Humira (adalimumab) from AbbVie, in combination with methotrexate is to be indicated for the treatment of active Polyarticular Juvenile Idiopathic Arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Humira has not been studied in children aged less than 2 years.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.